Myocardial Infarction
Cardiovascular 2 original drugsCardiovascular indication. Myocardial Infarction has 2 FDA-approved novel treatments, led by GE HLTHCARE INC, with 102 active industry clinical trials across 23 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Myocardial Infarction Market Leaders
Companies with the most FDA-approved novel Myocardial Infarction drugs.
Phase 3 Readouts Pro
5 active Phase 3 trials with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Myocardial Infarction Treatments by Mechanism
Top 8 mechanisms across 8 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Myocardial Infarction Clinical Pipeline by Phase
105 industry-sponsored trials across 79 sponsors
Novel Myocardial Infarction Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Myocardial Infarction.
Reformulations (29 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Myocardial Infarction Drug Targets
Molecular targets of approved and investigational Myocardial Infarction drugs — 23 targets tracked.
Generic Drugs (27 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs